Effective COMMISSION REGULATION (EU) No 640/2012 of 6 July 2012 amending, for the purpose of its adaptation to technical progress, Regulation (EC) No 440/2008 laying down test methods pursuant to Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) (Text with EEA relevance)
Vyhláška č. 640/2012
Important dates
Documents and links
COMMISSION REGULATION (EU) No 640/2012
of 6 July 2012
amending, for the purpose of its adaptation to technical progress, Regulation (EC) No 440/2008 laying down test methods pursuant to Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)
(Text with EEA relevance)
THE EUROPEAN COMMISSION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Regulation (EC) No 1907/2006 of 18 December 2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC (1), and in particular Article 13(3) thereof,
Whereas:
|
(1) |
Commission Regulation (EC) No 440/2008 (2) contains the test methods for the purposes of the determination of the physico-chemical properties, toxicity and eco-toxicity of substances to be applied for the purposes of Regulation (EC) No 1907/2006. |
|
(2) |
It is necessary to update Regulation (EC) No 440/2008 to include with priority new and updated alternative test methods recently adopted by the OECD, in order to obtain a reduction of the number of animals to be used for experimental purposes, in accordance with Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes (3) and Council Directive 86/609/EEC of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes (4). Stakeholders have been consulted on this draft. |
|
(3) |
Regulation (EC) No 440/2008 should therefore be amended accordingly. |
|
(4) |
The measures provided for in this Regulation are in accordance with the opinion of the Committee established under Article 133 of Regulation (EC) No 1907/2006, |
HAS ADOPTED THIS REGULATION:
Article 1
The Annex to Regulation (EC) No 440/2008 is amended in accordance with the Annex to this Regulation.
Article 2
This Regulation shall enter into force on the third day following that of its publication in the Official Journal of the European Union.
This Regulation shall be binding in its entirety and directly applicable in all Member States.
Done at Brussels, 6 July 2012.
For the Commission
The President
José MANUEL BARROSO
Prílohy
ANNEX
The Annex to Regulation (EC) No 440/2008 is amended as follows:
|
1. |
Chapter B.42 is replaced by the following: ‘B.42. SKIN SENSITISATION: LOCAL LYMPH NODE ASSAY INTRODUCTION
DEFINITIONS
INITIAL CONSIDERATIONS AND LIMITATIONS
PRINCIPLE OF THE TEST
DESCRIPTION OF THE ASSAY Selection of animal species
Housing and feeding conditions
Preparation of animals
Preparation of dosing solutions
Reliability check
TEST PROCEDURE Number of animals and dose levels
Pre-screen test
Main study experimental schedule
Preparation of cell suspensions
Determination of cellular proliferation (incorporated radioactivity)
Reduced LLNA
OBSERVATIONS Clinical observations
Body weights
CALCULATION OF RESULTS
DATA AND REPORTING Data
Test report
LITERATURE
Appendix 1 Performance standards for assessment of proposed similar or modified llna test methods for skin sensitisation INTRODUCTION
I. Essential test method components
II. Minimum list of reference chemicals
III. Defined reliability and accuracy standards
Intra-laboratory reproducibility
Inter-laboratory reproducibility
Appendix 2 Definitions Accuracy: The closeness of agreement between test method results and accepted reference values. It is a measure of test method performance and one aspect of relevance. The term is often used interchangeably with “concordance” to mean the proportion of correct outcomes of a test method (14). Benchmark substance: A sensitising or non-sensitising substance used as a standard for comparison to a test substance. A benchmark substance should have the following properties: (i) consistent and reliable source(s); (ii) structural and functional similarity to the class of substances being tested; (iii) known physicochemical characteristics; (iv) supporting data on known effects; and (v) known potency in the range of the desired response. Estimated concentration threshold (ECt): Estimated concentration of a test substance needed to produce a stimulation index that is indicative of a positive response. Estimated concentration three (EC3): Estimated concentration of a test substance needed to produce a stimulation index of three. False negative: A test substance incorrectly identified as negative or non-active by a test method, when in fact it is positive or active. False positive: A test substance incorrectly identified as positive or active by a test, when in fact it is negative or non-active. Hazard: The potential for an adverse health or ecological effect. The adverse effect is manifested only if there is an exposure of sufficient level. Inter-laboratory reproducibility: A measure of the extent to which different qualified laboratories, using the same protocol and testing the same test substances, can produce qualitatively and quantitatively similar results. Inter-laboratory reproducibility is determined during the pre-validation and validation processes, and indicates the extent to which a test can be successfully transferred between laboratories, also referred to as between-laboratory reproducibility (14). Intra-laboratory reproducibility: A determination of the extent that qualified people within the same laboratory can successfully replicate results using a specific protocol at different times. Also referred to as within-laboratory reproducibility (14). Me-too test: A colloquial expression for a test method that is structurally and functionally similar to a validated and accepted reference test method. Such a test method would be a candidate for catch-up validation. Interchangeably used with similar test method (14). Outlier: An outlier is an observation that is markedly different from other values in a random sample from a population. Performance standards (PS): Standards, based on a validated test method, that provide a basis for evaluating the comparability of a proposed test method that is functionally and mechanistically similar. Included are: (i) essential test method components; (ii) a minimum list of Reference Chemicals selected from among the chemicals used to demonstrate the acceptable performance of the validated test method; and (iii) the similar levels of accuracy and reliability, based on what was obtained for the validated test method, that the proposed test method should demonstrate when evaluated using the minimum list of Reference Chemicals (14). Proprietary test method: A test method for which manufacture and distribution is restricted by patents, copyrights, trademarks, etc. Quality assurance: A management process by which adherence to laboratory testing standards, requirements, and record keeping procedures, and the accuracy of data transfer, are assessed by individuals who are independent from those performing the testing. Reference chemicals: Chemicals selected for use in the validation process, for which responses in the in vitro or in vivo reference test system or the species of interest are already known. These chemicals should be representative of the classes of chemicals for which the test method is expected to be used, and should represent the full range of responses that may be expected from the chemicals for which it may be used, from strong, to weak, to negative. Different sets of reference chemicals may be required for the different stages of the validation process, and for different test methods and test uses (14). Relevance: Description of relationship of the test to the effect of interest and whether it is meaningful and useful for a particular purpose. It is the extent to which the test correctly measures or predicts the biological effect of interest. Relevance incorporates consideration of the accuracy (concordance) of a test method (14). Reliability: Measures of the extent that a test method can be performed reproducibly within and between laboratories over time, when performed using the same protocol. It is assessed by calculating intra- and inter-laboratory reproducibility (14). Skin sensitisation: An immunological process that results when a susceptible individual is exposed topically to an inducing chemical allergen, which provokes a cutaneous immune response that can lead to the development of contact sensitisation. Stimulation Index (SI): A value calculated to assess the skin sensitisation potential of a test substance that is the ratio of the proliferation in treated groups to that in the concurrent vehicle control group. Test substance (also referred to as test chemical): Any substance or mixture tested using this TM. Validated test method: A test method for which validation studies have been completed to determine the relevance (including accuracy) and reliability for a specific purpose. It is important to note that a validated test method may not have sufficient performance in terms of accuracy and reliability to be found acceptable for the proposed purpose (14). |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
2. |
Chapter B.46 is replaced by the following: ‘B.46. IN VITRO SKIN IRRITATION: RECONSTRUCTED HUMAN EPIDERMIS TEST METHOD INTRODUCTION
DEFINITIONS
INITIAL CONSIDERATIONS AND LIMITATIONS
PRINCIPLE OF THE TEST
DEMONSTRATION OF PROFICIENCY
PROCEDURE
RhE Test Method Components General conditions
Functional conditions Viability
Barrier function
Morphology
Reproducibility
Quality control (QC)
Application of the Test and Control Chemicals
Cell Viability Measurements
Acceptability Criteria
Interpretation of Results and Prediction Model
DATA AND REPORTING Data
Test Report
LITERATURE
Appendix 1 Definitions Accuracy: The closeness of agreement between test method results and accepted reference values. It is a measure of test method performance and one aspect of relevance. The term is often used interchangeably with “concordance” to mean the proportion of correct outcomes of a test method (9). Cell viability: Parameter measuring total activity of a cell population e.g. as ability of cellular mitochondrial dehydrogenases to reduce the vital dye MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Thiazolyl blue), which depending on the endpoint measured and the test design used, correlates with the total number and/or vitality of living cells. Concordance: This is a measure of test method performance for test methods that give a categorical result, and is one aspect of relevance. The term is used interchangeably with accuracy, and is defined as the proportion of all chemicals tested that are correctly classified as positive or negative. (9). ET50 : Can be estimated by determination of the exposure time required to reduce cell viability by 50 % upon application of the marker chemical at a specified, fixed concentration, see also IC50. EU CLP (Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of Substances and Mixtures): Implements in the European Union (EU) the UN GHS system for the classification and labelling of chemicals (substances and mixtures) (3). GHS (Globally Harmonised System of Classification and Labelling of Chemicals by the United Nations (UN)): A system proposing the classification of chemicals (substances and mixtures) according to standardised types and levels of physical, health and environmental hazards, and addressing corresponding communication elements, such as pictograms, signal words, hazard statements, precautionary statements and safety data sheets, so that to convey information on their adverse effects with a view to protect people (including employers, workers, transporters, consumers and emergency responders) and the environment (1). IC50 : Can be estimated by determination of the concentration at which a marker chemical reduces the viability of the tissues by 50 % (IC50) after a fixed exposure time, see also ET50. Infinite dose: Amount of test chemical applied to the epidermis exceeding the amount required to completely and uniformly cover the epidermis surface. Me-too test: A colloquial expression for a test method that is structurally and functionally similar to a validated and accepted reference test method. Such a test method would be a candidate for catch-up validation. Interchangeably used with similar test method (9). Performance standards (PS): Standards, based on a validated test method, that provide a basis for evaluating the comparability of a proposed test method that is mechanistically and functionally similar. Included are; (i) essential test method components; (ii) a minimum list of Reference Chemicals selected from among the chemicals used to demonstrate the acceptable performance of the validated test method; and (iii) the comparable levels of accuracy and reliability, based on what was obtained for the validated test method, that the proposed test method should demonstrate when evaluated using the minimum list of Reference Chemicals (9). Reference chemicals: Chemicals selected for use in the validation process, for which responses in the in vitro or in vivo reference test system or the species of interest are already known. These chemicals should be representative of the classes of chemicals for which the test method is expected to be used, and should represent the full range of responses that may be expected from the chemicals for which it may be used, from strong, to weak, to negative. Different sets of reference chemicals may be required for the different stages of the validation process, and for different test methods and test uses (9). Relevance: Description of relationship of the test to the effect of interest and whether it is meaningful and useful for a particular purpose. It is the extent to which the test correctly measures or predicts the biological effect of interest. Relevance incorporates consideration of the accuracy (concordance) of a test method (9). Reliability: Measures of the extent that a test method can be performed reproducibly within and between laboratories over time, when performed using the same protocol. It is assessed by calculating intra- and inter-laboratory reproducibility (9). Replacement test: A test which is designed to substitute for a test that is in routine use and accepted for hazard identification and/or risk assessment, and which has been determined to provide equivalent or improved protection of human or animal health or the environment, as applicable, compared to the accepted test, for all possible testing situations and chemicals (9). Sensitivity: The proportion of all positive/active test chemicals that are correctly classified by the test. It is a measure of accuracy for a test method that produces categorical results, and is an important consideration in assessing the relevance of a test method (9). Skin irritation: The production of reversible damage to the skin following the application of a test chemical for up to 4 hours. Skin irritation is a locally arising, non-immunogenic reaction, which appears shortly after stimulation (29). Its main characteristic is its reversible nature involving inflammatory reactions and most of the clinical characteristic signs of irritation (erythema, oedema, itching and pain) related to an inflammatory process. Specificity: The proportion of all negative/inactive test chemicals that are correctly classified by the test. It is a measure of accuracy for a test method that produces categorical results and is an important consideration in assessing the relevance of a test method (9). Tiered testing strategy: Testing which uses test methods in a sequential manner; the test methods selected in each succeeding level are decided based on the results in the previous level of testing (9). Test chemical (also referred to as test substance): Any substance or mixture tested using this TM. Appendix 2 Performance Standards for assessment of proposed similar or modified in vitro reconstructed human epidermis (RhE) methods for skin irritation INTRODUCTION
PERFORMANCE STANDARDS FOR IN VITRO RhE TEST METHODS FOR SKIN IRRITATION
I) Essential Test Method Components
II) Minimum List of Reference Chemicals
III) Defined Reliability and Accuracy Values
Within-laboratory reproducibility
Between-laboratory reproducibility
Predictive capacity (accuracy)
Study Acceptance Criteria
|
|
3. |
The following Chapters are added: ‘B.49. IN VITRO MAMMALIAN CELL MICRONUCLEUS TEST INTRODUCTION
DEFINITIONS
INITIAL CONSIDERATIONS
PRINCIPLE OF THE TEST
DESCRIPTION OF THE ASSAY Preparations
Media and culture conditions
Preparation of cultures
Metabolic activation
Test substance preparation
Test Conditions Solvents/vehicles
Use of cytoB as a cytokinesis blocker
Measuring cell proliferation and cytotoxicity and choosing exposure concentrations
Controls
TEST PROCEDURE Treatment Schedule
Lymphocytes, primary cells, and cell lines with cytoB
Cell lines without cytoB
Number of cultures
Cell harvest and slide preparation
Analysis
Acceptability criteria
DATA AND REPORTING Treatment of results
Evaluation and interpretation of results
Test Report
LITERATURE
Appendix 1 Definitions Aneugen: any substance or process that, by interacting with the components of the mitotic and meiotic cell division cycle, leads to aneuploidy in cells or organisms. Aneuploidy: any deviation from the normal diploid (or haploid) number of chromosomes by a single chromosome or more than one, but not by entire set(s) of chromosomes (polyploidy). Apoptosis: programmed cell death characterised by a series of steps leading to a disintegration of cells into membrane-bound particles that are then eliminated by phagocytosis or by shedding. Cell proliferation: increase in cell number as a result of mitotic cell division. Centromere: DNA region of a chromosome where both chromatids are held together and on which both kinetochores are attached side-to-side. Clastogen: any substance or process which causes structural chromosomal aberrations in populations of cells or organisms. Cytokinesis: the process of cell division immediately following mitosis to form two daughter cells, each containing a single nucleus. Cytokinesis-Block Proliferation index (CBPI): the proportion of second-division cells in the treated population relative to the untreated control (see Appendix 2 for formula). Cytostasis: inhibition of cell growth (see Appendix 2 for formula). Cytotoxicity: harmful effects to cell structure or function ultimately causing cell death. Genotoxic: a general term encompassing all types of DNA or chromosome damage, including breaks, adducts rearrangements, mutations, chromosome aberrations, and aneuploidy. Not all types of genotoxic effects result in mutations or stable chromosome damage. Interphase cells: cells not in the mitotic stage. Kinetochore: a protein-containing structure that assembles at the centromere of a chromosome to which spindle fibres associate during cell division, allowing orderly movement of daughter chromosomes to the poles of the daughter cells. Micronuclei: small nuclei, separate from and additional to the main nuclei of cells, produced during telophase of mitosis or meiosis by lagging chromosome fragments or whole chromosomes. Mitosis: division of the cell nucleus usually divided into prophase, prometaphase, metaphase, anaphase and telophase. Mitotic index: the ratio of cells in metaphase divided by the total number of cells observed in a population of cells; an indication of the degree of cell proliferation of that population. Mutagenic: produces a heritable change of DNA base-pair sequences(s) in genes or of the structure of chromosomes (chromosome aberrations). Non-disjunction: failure of paired chromatids to disjoin and properly segregate to the developing daughter cells, resulting in daughter cells with abnormal numbers of chromosomes. Polyploidy: numerical chromosome aberrations in cells or organisms involving entire set(s) of chromosomes, as opposed to an individual chromosome or chromosomes (aneuploidy). Proliferation Index (PI): method for cytotoxicity measurement when cytoB is not used (see Appendix 2 for formula). Relative Increase in Cell Count (RICC): method for cytotoxicity measurement when cytoB is not used (see Appendix 2 for formula). Relative Population Doubling (RPD): method for cytotoxicity measurement when cytoB is not used (see Appendix 2 for formula). Replication Index (RI): the proportion of cell division cycles completed in a treated culture, relative to the untreated control, during the exposure period and recovery (see Appendix 2 for formula). Test chemical (also referred to as test substance): Any substance or mixture tested using this TM. Appendix 2 Formulas for Cytotoxicity Assessment
Appendix 3 Reference chemicals recommended for assessing performance (14)
B.50. SKIN SENSITISATION: LOCAL LYMPH NODE ASSAY: DA INTRODUCTION
DEFINITIONS
INITIAL CONSIDERATIONS AND LIMITATIONS
PRINCIPLE OF THE TEST METHOD
DESCRIPTION OF THE ASSAY Selection of animal species
Housing and feeding conditions
Preparation of animals
Preparation of dosing solutions
Reliability check
TEST PROCEDURE Number of animals and dose levels
Pre-screen test
Main study experimental schedule
Preparation of cell suspensions
Determination of cellular proliferation (measurement of ATP content of lymphocytes)
OBSERVATIONS Clinical observations
Body weights
CALCULATION OF RESULTS
DATA AND REPORTING Data
Test report
LITERATURE
Appendix 1 DEFINITIONS Accuracy: The closeness of agreement between test method results and accepted reference values. It is a measure of test method performance and one aspect of relevance. The term is often used interchangeably with “concordance” to mean the proportion of correct outcomes of a test method (38). Benchmark substance: A sensitising or non-sensitising substance used as a standard for comparison to a test substance. A benchmark substance should have the following properties; (i) a consistent and reliable source(s); (ii) structural and functional similarity to the class of substances being tested; (iii) known physicochemical characteristics; (iv) supporting data on known effects, and (v) known potency in the range of the desired response. False negative: A substance incorrectly identified as negative or non-active by a test method, when in fact it is positive or active. False positive: A substance incorrectly identified as positive or active by a test, when in fact it is negative or non-active. Hazard: The potential for an adverse health or ecological effect. The adverse effect is manifested only if there is an exposure of sufficient level. Inter-laboratory reproducibility: A measure of the extent to which different qualified laboratories, using the same protocol and testing the same test substances, can produce qualitatively and quantitatively similar results. Inter-laboratory reproducibility is determined during the pre-validation and validation processes, and indicates the extent to which a test can be successfully transferred between laboratories, also referred to as between-laboratory reproducibility (38). Intra-laboratory reproducibility: A determination of the extent that qualified people within the same laboratory can successfully replicate results using a specific protocol at different times. Also referred to as within-laboratory reproducibility (38). Outlier: An outlier is an observation that is markedly different from other values in a random sample from a population. Quality assurance: A management process by which adherence to laboratory testing standards, requirements, and record keeping procedures, and the accuracy of data transfer, are assessed by individuals who are independent from those performing the testing. Reliability: Measures of the extent that a test method can be performed reproducibly within and between laboratories over time, when performed using the same protocol. It is assessed by calculating intra- and inter-laboratory reproducibility (38). Skin sensitisation: An immunological process that results when a susceptible individual is exposed topically to an inducing chemical allergen, which provokes a cutaneous immune response that can lead to the development of contact sensitisation. Stimulation Index (SI): A value calculated to assess the skin sensitisation potential of a test substance that is the ratio of the proliferation in treated groups to that in the concurrent vehicle control group. Test substance (also referred to as test chemical): Any substance or mixture tested using this TM. B.51. SKIN SENSITISATION: LOCAL LYMPH NODE ASSAY: BrdU-ELISA INTRODUCTION
DEFINITIONS
INITIAL CONSIDERATIONS AND LIMITATIONS
PRINCIPLE OF THE TEST METHOD
DESCRIPTION OF THE ASSAY Selection of animal species
Housing and feeding conditions
Preparation of animals
Preparation of dosing solutions
Reliability check
TEST PROCEDURE Number of animals and dose levels
Pre-screen test
Main study experimental schedule
Preparation of cell suspensions
Determination of cellular proliferation (measurement of BrdU content in DNA of lymphocytes)
OBSERVATIONS Clinical observations
Body weights
CALCULATION OF RESULTS
DATA AND REPORTING Data
Test report
LITERATURE
Appendix 1 DEFINITIONS Accuracy: The closeness of agreement between test method results and accepted reference values. It is a measure of test method performance and one aspect of relevance. The term is often used interchangeably with “concordance” to mean the proportion of correct outcomes of a test method (33). Benchmark substance: A sensitising or non-sensitising substance used as a standard for comparison to a test substance. A benchmark substance should have the following properties: (i) a consistent and reliable source(s); (ii) structural and functional similarity to the class of substances being tested; (iii) known physical/chemical characteristics; (iv) supporting data on known effects; and (v) known potency in the range of the desired response. False negative: A test substance incorrectly identified as negative or non-active by a test method, when in fact it is positive or active (33). False positive: A test substance incorrectly identified as positive or active by a test, when in fact it is negative or non-active (33). Hazard: The potential for an adverse health or ecological effect. The adverse effect is manifested only if there is an exposure of sufficient level. Inter-laboratory reproducibility: A measure of the extent to which different qualified laboratories, using the same protocol and testing the same test substance, can produce qualitatively and quantitatively similar results. Inter-laboratory reproducibility is determined during the pre-validation and validation processes, and indicates the extent to which a test can be successfully transferred between laboratories, also referred to as between-laboratory reproducibility (33). Intra-laboratory reproducibility: A determination of the extent that qualified people within the same laboratory can successfully replicate results using a specific protocol at different times. Also referred to as within-laboratory reproducibility (33). Outlier: An outlier is an observation that is markedly different from other values in a random sample from a population. Quality assurance: A management process by which adherence to laboratory testing standards, requirements, and record keeping procedures, and the accuracy of data transfer, are assessed by individuals who are independent from those performing the testing. Reliability: Measures of the extent that a test method can be performed reproducibly within and between laboratories over time, when performed using the same protocol. It is assessed by calculating intra- and inter-laboratory reproducibility (33). Skin sensitisation: An immunological process that results when a susceptible individual is exposed topically to an inducing chemical allergen, which provokes a cutaneous immune response that can lead to the development of contact sensitisation. Stimulation Index (SI): A value calculated to assess the skin sensitisation potential of a test substance that is the ratio of the proliferation in treated groups to that in the concurrent vehicle control group. Test substance (also referred to as test chemical): Any substance or mixture tested using this TM. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Poznámky
(*1) Presumed to be a non-sensitiser in humans based on the fact that no clinical patch test results were located, it is not included as a patch test kit allergen, and no case reports of human sensitisation were located.
(*2) GP data not available.
(1) Chemicals should be prepared daily unless stability data demonstrate the acceptability of storage.
(2) Because of the potential impact of different vehicles on the performance of the LLNA, the recommended vehicle for each reference chemical should be used (24) (32).
(3) Mean value where more than one EC3 value was available. For negative substances (i.e. with stimulation index < 3, the highest concentration tested is provided).
(4) Number of LLNA studies from which data were obtained.
(5) Commercially available as Kathon CG (CAS No 55965-84-9), which is a 3:1 mixture of CMI and MI. The relative concentrations of each component range from 1,1 % to 1,25 % (CMI) and 0,3 % to 0,45 % (MI). The inactive components are magnesium salts (21,5 % to 24 %) and copper nitrate (0,15 % to 0,17 %), with the remaining formulation 74 % to 77 % water. Kathon CG is readily available through Sigma-Aldrich and Rohm and Haas (now Dow Chemical Corporation).
(6) These Reference Chemicals are a subset of the Reference Chemicals used in the validation study.
(7) In vivo score in accordance with B.4 and OECD Test Guideline 404 (4).
(8) Under this Test Method, the UN GHS optional Category 3 (mild irritants) (1) is considered as No Category.
(9) The UN GHS optional Category3 is not applicable under the EU CLP.
(11) The chemical selection is based on the following criteria: (i) the chemicals are commercially available; (ii) they are representative of the full range of Draize irritancy scores (from non-irritant to strong irritant); (iii) they have a well-defined chemical structure; (iv) they are representative of the chemical functionality used in the validation process; and (v) they are not associated with an extremely toxic profile (e.g. carcinogenic or toxic to the reproductive system) and they are not associated with prohibitive disposal costs.
(12) Chemicals that are irritant in the rabbit but for which there is reliable evidence that they are non-irritant in humans (31) (32) (33).
(13) Under the UN GHS, not in the EU CLP
(14) The reference chemicals are the recommended chemicals for use. Substitution or adding of chemicals to the list of reference chemicals can be done if their activity is known and if they induce micronuclei by the same mechanisms of action, and if they are shown to be relevant to the chemicals that will be tested using the MNvit procedure. Depending on the purpose, justification could also include a validation study employing a broad variety of substances or focused on a narrower spectrum based on the chemical class of the test substance or the mechanism of damage being studied.